Full-Time

Principal Statistical Programmer

Posted on 9/18/2025

SpringWorks Therapeutics

SpringWorks Therapeutics

201-500 employees

Clinical-stage precision medicines for cancer

Compensation Overview

$160k - $260k/yr

Durham, NC, USA

Hybrid

Must be available to work in office two days a week.

Category
Biology & Biotech (4)
, , ,
Required Skills
SAS
SQL
Linux/Unix
Requirements
  • Master’s degree or foreign degree equivalent in Mathematics, Statistics, Biostatistics, Computer Science, Data Science, or related field
  • Five (5) years of experience in Statistical Programming/ SAS Programming-related role or in the job offered
  • Understanding of regulatory requirements for drug approval such as FDA, European Medicines Agency (EMA), Prescription Drug Marketing Act (PDMA)
  • Knowledge of Clinical Data Interchange Standards Consortium (CDISC) standards for conducting clinical trials
  • SAS language for conducting clinical trials, including Base SAS, macro, SAS/STAT, SAS/GRAPH, SAS/Macro, and SQL
  • Creating define.xml, Pinnacle 21, ADRG, SDRG for clinical studies submissions to FDA, EMA, and Japan
  • Leading programming activities and timelines using tools such as Windows and Linux Operating Systems
  • Cross functional collaboration with Clinical Operations, Project Management, Data Management, Statistician, and Pharmacovigilance using project management tools such as Microsoft Project or SmartSheet.
Responsibilities
  • Serves as a subject matter expert who develops all files using features in SAS and other programming languages
  • Performs quality control checks of SAS code and output produced by other Statistical Programmers
  • Independently and collaboratively solves complex clinical trial reporting problems
  • Works cross-functionally within Biometrics, including Statistical Programmers, Biostatisticians, Data Management, and other departments
  • Provides technical and project management skills to create, review, and approve documentation required to support data analysis, reporting, and CDLSC data submission
  • Creates and maintains project timelines, delegating programming assignments to internal and external programming resources
  • Trains and onboards new staff, both internal and external and serves as a mentor to other statistical programmers at lower levels.
SpringWorks Therapeutics

SpringWorks Therapeutics

View

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicines for patients with rare diseases and cancer. Its approach is to tailor therapies based on the genetic and molecular profile of a disease, aiming to improve treatment effectiveness and safety for underserved patient groups. The company advances drug candidates through clinical trials (such as Phase 1b and 2) and pursues partnerships with other pharmaceutical companies to acquire, develop, and commercialize therapies. Unlike broader, non-targeted programs, SpringWorks focuses on niche patient populations defined by genetic profiles and collaborates on development and commercialization, broadening access to targeted treatments. The company’s goal is to bring targeted therapies to market that address unmet medical needs in oncology and rare diseases, improving outcomes for patients with specific genetic conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck KGaA acquired SpringWorks for $3.9B on July 1, 2025.
  • Acquisition adds immediate revenue from Ogsiveo and Gomekli.
  • CHMP positive opinion for mirdametinib expands EU access.

What critics are saying

  • Merck KGaA drops two SpringWorks pipeline assets post-acquisition.
  • European Commission rejects mirdametinib approval due to pediatric data.
  • Pimicotinib outperforms Ogsiveo in desmoid tumor trials.

What makes SpringWorks Therapeutics unique

  • Ogsiveo is first FDA-approved therapy for desmoid tumors.
  • Gomekli is first approved therapy for NF1-PN in adults and children.
  • Precision medicines target rare cancers via genetic profiling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Professional Development Budget

Flexible Work Hours

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

5%

2 year growth

5%
AllSci
Mar 17th, 2026
R1 Therapeutics launches with oversubscribed USD 77.5m Series A.

R1 Therapeutics launches with oversubscribed USD 77.5m Series A. March 17, 2026 R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A financing totaling USD 77.5 million. The company is focused on developing therapies for chronic kidney disease, the lead program targeting hyperphosphatemia in dialysis patients. R1 acquired exclusive global rights outside of Greater China to that program - AP306, a pan phosphate transporter inhibitor - via a license deal with China-based Alebund Pharmaceuticals announced alongside the Series A. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), with participation from Curie.Bio, SymBiosis, and US Renal Care. The company said proceeds will fund a global development program for AP306, including a Phase IIb study planned to begin later this year. This is R1 Therapeutics' first disclosed funding round, coinciding with the company's formal launch. AP306, previously known as EOS789, was originally discovered by Chugai Pharmaceutical Co. and subsequently licensed to Alebund Pharmaceuticals, which conducted a Phase IIa study in hemodialysis patients in China. Results from that trial, published in Kidney International Reports, showed statistically significant reductions in serum phosphate with a tolerable safety profile. AP306 is described as the only clinical-stage agent that blocks active phosphate transport via three GI-tract transporters - NaPi-2b, PiT-1, and PiT-2 - distinguishing it from phosphate binders, which inhibit passive transport and have been the standard of care for six decades. More than 40% of US dialysis patients fail to reach phosphate targets with existing therapies, which carry high pill burden and GI tolerability issues, the company said. R1 is led by co-founder, president, and CEO Krishna Polu, M.D., a nephrologist with more than 20 years of biopharmaceutical experience. Co-founder L. Mary Smith, Ph.D., who previously served as chief development officer at SpringWorks Therapeutics, joins as chief operating officer. Your email address will not be published. Required fields are marked *

PharmiWeb.com
May 27th, 2025
Springworks Therapeutics Receives Positive Chmp Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With Nf1-Pn

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN. – If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –. – Decision from European Commission expected in the third quarter of 2025 –

Merck Group
May 5th, 2025
agreement-to-acquire-springworks

Merck KGaA, Darmstadt, Germany, and SpringWorks Therapeutics, have entered into a definitive agreement for us to acquire SpringWorks.

MedCity News
Apr 28th, 2025
Merck KGaA's Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition

When SpringWorks went public in 2019, the biotech priced its shares at $18 each.

IT Juzi
Apr 28th, 2025
Merck Acquires SpringWorks for $3.9B

German Merck Group has announced a $3.9 billion acquisition agreement with U.S. biopharmaceutical company SpringWorks Therapeutics. This acquisition aims to enhance Merck's cancer drug business. SpringWorks Therapeutics, a biopharmaceutical developer, has obtained four potential new drugs in clinical stages from Pfizer.

INACTIVE